Endocyte Loss Narrows, Reports Development Progress

Posted: Updated:
The company specializes in precision medicine and molecules. The company specializes in precision medicine and molecules.
WEST LAFAYETTE -

West Lafayette-based Endocyte Inc. (Nasdaq: ECYT) is reporting a second quarter net loss of $11.7 million, compared to a net loss of $14 million a year ago. Despite the loss, Chief Executive Officer Mike Sherman says he is optimistic about progress being made on three development programs.

Sherman says the biopharmaceutical company's research and development partnership announced in March with Seattle Children's Research Institute is exceeding expectations, leading to expectations that Endocyte's chimeric antigen receptor T-cell therapy will enter the manufacturing process by the end of the year. He adds an Investigational New Drug Application has been filed for the company's EC2629 agent, which it says is the first of its kind that "simultaneously targets cancer cells and the tumor associated macrophages that support and protect them." Enrollment of taxane-exposed prostate cancer patients in another important trial is also expected to be complete this fall.

Sherman added in Endocyte's earnings report:

We believe our pipeline has significant potential to create value and we are committed to effective, timely execution in bringing these assets forward through clinical development and identifying paths to accelerate value-driving catalysts. With this in mind, our strategy is to select receptor-positive patients in highly-targeted indications from the beginning of development, including during dose escalation. We will also continue to objectively measure our pipeline investments relative to opportunities to outlicense assets or access external opportunities to ensure we are deploying capital productively.

You can connect to more about the company's Q2 earnings report by clicking here.

In June, Endocyte announced a restructuring that included a 40 percent reduction in its work force.

  • Perspectives

    • How Telling Your Customers 'No' Can Improve Loyalty

      Business usually try to convert customers into loyalists by giving them what they want. That statement seems obvious... until it's not. Take Milktooth in Indianapolis, for example. The restaurant has become a star of the food scene by telling customers "no." This flies in the face of what most businesses consider to be standard operating procedure. But for Milktooth, saying no is simply good business.

    More

Subscribe

Name:
Company Name:
Email:
Confirm Email:
HTML
INside Edge
Morning Briefing
BigWigs & New Gigs
Life Sciences Indiana
Indiana Connections
INPower
Subscribe
Unsubscribe

Events



  • Most Popular Stories

    • ‘Invisible’ Digital Twins Taking Flight at GE Aviation

      As aircraft engines roll off the production line at GE Aviation in Lafayette, workers there are also producing “ghost” engines of sorts, called digital twins. 

    • Construction to Begin on $15M Noblesville Fieldhouse

      City and development officials will break ground Friday on a $15 million sports complex in Noblesville. Finch Creek Park Fieldhouse will include five courts with hard surfaces, two turf-surfaced fields and 11 batting and pitching cages. The project, which was first unveiled a year ago, is a public-private partnership between Klipsch-Card Athletic Facilities LLC and the city. The company is also owner/operator of the fieldhouse at Grand Park in Westfield.

    • Historic Indy Building to Become Hotel

      A nearly 110-year-old building in downtown Indianapolis will soon have new life. Indianapolis-based real estate development firm Loftus Robinson is partnering with Kimpton Hotels & Restaurants in California to transform the former Odd Fellows building into a 130-room hotel with a signature restaurant. Financial terms of the project are not being disclosed, however the developer says the hotel is scheduled to open in early 2020 and create about 150 hotel and restaurant jobs.

    • Lilly Cancer Treatment Falls Short in Study

      Indianapolis-based Eli Lilly and Co. (NYSE: LLY) has announced it will not seek regulatory approval on another use for one of the key treatments in its cancer portfolio. In a late-stage study, CYRAMZA met its main goal of progression free-survival in patients with HER2-negative metastatic gastric or gastroesophageal junction adenocarcinoma, but did not improve a secondary endpoint: overall survival rate.

    • How Telling Your Customers 'No' Can Improve Loyalty

      Business usually try to convert customers into loyalists by giving them what they want. That statement seems obvious... until it's not. Take Milktooth in Indianapolis, for example. The restaurant has become a star of the food scene by telling customers "no." This flies in the face of what most businesses consider to be standard operating procedure. But for Milktooth, saying no is simply good business.